Concepedia

Kelli Gaskins

KG

Statistics

Publications

8

Citations

419

H-Index

8

Active since

2016

Affiliations

National Cancer Institute(Current)

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

Stanford University

National Center for Advancing Translational Sciences

Kelli Gaskins is an author at National Cancer Institute specializing in oncology, molecular oncology, and medicine.

Publications per year

2016–2020

8

Publications

8

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer <i>In Vitro</i> and <i>In Vivo</i>

Shilpa Thakur, Brianna Daley, Kelli Gaskins et al. · Clinical Cancer Research · 2018 · 161 citations · Full text

, , +17

Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases

Shweta Kotian, Lisa Zhang, Myriem Boufraqech et al. · Clinical Cancer Research · 2017 · 88 citations

, , +17

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma

M. Jain, Kelli Gaskins, S Wang et al. · Oncogene · 2017 · 64 citations

, , +13

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response

Naris Nilubol, Myriem Boufraqech, Lisa Zhang et al. · Oncotarget · 2018 · 30 citations · Full text

, , +17

Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors

Naris Nilubol, Ziqiang Yuan, Giulio F. Paciotti et al. · JNCI Journal of the National Cancer Institute · 2018 · 23 citations · Full text

, , +17

1–5 of 8